This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 24;12(2):83.

doi: 10.1038/nrc3213.

Bevacizumab in ovarian cancer

No authors listed

PMID: 22270952
DOI: 10.1038/nrc3213

Comment

Bevacizumab in ovarian cancer

No authors listed. Nat Rev Cancer. 2012.

. 2012 Jan 24;12(2):83.

doi: 10.1038/nrc3213.

PMID: 22270952
DOI: 10.1038/nrc3213

No abstract available

PubMed Disclaimer

Comment on

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Burger RA, et al. N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390. N Engl J Med. 2011. PMID: 22204724 Clinical Trial.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Clinical Trial.

Similar articles

The role of bevacizumab in advanced epithelial ovarian cancer.
Kroep JR, Nortier JW. Kroep JR, et al. Curr Pharm Des. 2012;18(25):3775-83. doi: 10.2174/138161212802002689. Curr Pharm Des. 2012. PMID: 22591420
Critical appraisal of bevacizumab in the treatment of ovarian cancer.
Yoshida H, Yabuno A, Fujiwara K. Yoshida H, et al. Drug Des Devel Ther. 2015 Apr 28;9:2351-8. doi: 10.2147/DDDT.S83275. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25960638 Free PMC article. Review.
Bevacizumab and its use in epithelial ovarian cancer.
Matulonis UA. Matulonis UA. Future Oncol. 2011 Mar;7(3):365-79. doi: 10.2217/fon.10.167. Epub 2011 Feb 16. Future Oncol. 2011. PMID: 21323425
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T, Komiyama S, Kigawa J, Tanabe H, Kato K, Itamochi H, Fujiwara H, Kamiura S, Hamano T, Sugiyama T; Japanese Gynecologic Oncology Group. Shoji T, et al. BMC Cancer. 2018 Jul 31;18(1):771. doi: 10.1186/s12885-018-4505-4. BMC Cancer. 2018. PMID: 30064406 Free PMC article. Clinical Trial.
Bevacizumab in the treatment of ovarian cancer.
Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, Heitz J, Kurzeder C, du Bois A. Heitz F, et al. Adv Ther. 2012 Sep;29(9):723-35. doi: 10.1007/s12325-012-0041-9. Epub 2012 Aug 21. Adv Ther. 2012. PMID: 22941523 Review.

See all similar articles

Cited by

Trial watch: Dendritic cell-based anticancer therapy.
Bloy N, Pol J, Aranda F, Eggermont A, Cremer I, Fridman WH, Fučíková J, Galon J, Tartour E, Spisek R, Dhodapkar MV, Zitvogel L, Kroemer G, Galluzzi L. Bloy N, et al. Oncoimmunology. 2014 Dec 21;3(11):e963424. doi: 10.4161/21624011.2014.963424. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941593 Free PMC article. Review.

References

1. N Engl J Med. 2011 Dec 29;365(26):2473-83 - PubMed
1. N Engl J Med. 2011 Dec 29;365(26):2484-96 - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group